Cantor Fitzgerald Keeps Their Buy Rating on Avidity Biosciences (RNA)
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
Merus Price Target Maintained With a $67.00/Share by Canaccord Genuity
Merus Analyst Ratings
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $38
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Buy Rating Affirmed for Merus on Promising Petosemtamab Trials and $67 Price Target
Alkermes Price Target Raised to $37.00/Share From $35.00 by HC Wainwright & Co.
Alkermes Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
Strong Performance and Clinical Promise Uphold Buy Rating for Alkermes With $32 Target Price
Buy Rating for Alkermes Supported by Strong Q2 Performance and Promising Pipeline Potential
Arcellx Price Target Maintained With a $85.00/Share by Canaccord Genuity
Arcellx Analyst Ratings
Buy Rating Affirmed on Arcellx Inc for Its Innovative Multiple Myeloma Treatments and Competitive Market Position
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Elevance Health (ELV) and Johnson & Johnson (JNJ)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Buy Rating Affirmed for Immunovant Amidst Market Expansion and Promising Clinical Trials
Alkermes Analyst Ratings